Scancell Holdings (SCLP) highlighted significant progress in its melanoma vaccine program iSCIB1+ during a presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The company’s Phase II trial results, which included 132 patients across four cohorts, demonstrated a 62% overall response rate and an 81% disease control rate. When combined with Ipilimumab and Nivolumab, the vaccine achieved a 77% progression-free survival rate at 22 months—a 34 percentage-point improvement over the 43% PFS observed in the CheckMate 067 study, which used the same combination of checkpoint inhibitors alone. In a Phase I monotherapy trial for resectable melanoma, iSCIB1+ delivered a 75% recurrence-free survival rate at 39 months, surpassing the 63% standard of care with surgery plus pembrolizumab.
Scancell’s Melanoma Vaccine Nears Phase III as Phase II Data Shows 62% Response Rate
Scancell Holdings reported promising interim results from its iSCIB1+ melanoma vaccine in Phase II trials, with a 62% overall response rate and a 34 percentage-point improvement in progression-free survival versus existing treatments. The company is advancing toward Phase III enrollment, targeting a 550-patient global study by late 2026.
SL
Sophie Laurent · FX & Rates Desk · 18 Sept 2026 · 11:00 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
